← Back
Data updated: Jul 17, 2026
GEN ELECTRIC
Pharma Pharmaceuticals
GEN ELECTRIC is a pharmaceutical company with 1 FDA-approved products.
1976
Since
1
Drugs
-
Trials
0
New Drugs (2yr)
Modality:
1 Small Molecules
Upcoming FDA Decisions
Full Calendar → Aug 19, 2026 — Garetosmab
Aug 23, 2026 — DTX401 (pariglasgene brecaparvovec)
Oct 17, 2026 — Phentolamine ophthalmic solution 0.75%
GEN ELECTRIC's Key Drugs
GEN ELECTRIC's key approved drugs from the last 15 years (excludes generics, biosimilars and IV formulations).
No active drugs
GEN ELECTRIC's Recent FDA Approvals
New NDA/BLA approvals for GEN ELECTRIC over the last two years — novel drugs only, excluding generics and label supplements.
No recent approvals
GEN ELECTRIC's Therapeutic Areas
Disease areas where GEN ELECTRIC has approved drugs and an active pipeline. Weighted by commercial stage — approved drugs count most, then late-stage trials.
No indication data
GEN ELECTRIC Pipeline Snapshot
Active clinical trials for GEN ELECTRIC across all therapeutic areas, from ClinicalTrials.gov.
No active pipeline data available
Pro Expected Approvals & Milestones
Loading detailed analysis...
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • Top drug revenue breakdown
- • Drug-level revenue analysis
Trial Catalysts
- • Active trial monitoring
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Unlock Full Intelligence
Revenue forecasts • Trial milestones • Patent risk modeling
Active (0)
Discontinued (0)
Company Info
- First Approval
- 1976-03-24
- Latest
- 1986-07-31
- Applications
- 1